MCID: CLL010
MIFTS: 59

Cellular Ependymoma

Categories: Cancer diseases, Genetic diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cellular Ependymoma

MalaCards integrated aliases for Cellular Ependymoma:

Name: Cellular Ependymoma 11 19 14 71
Ependymoma 19 58 75 28 53 5 16 71
Tanycytic Ependymoma 19 71
Papillary Ependymoma 19 71
Classic Ependymoma 19 58
Who Grade Ii Ependymal Neoplasm 19
Epithelial Ependymoma 19
Clear Cell Ependymoma 19
Ependymoma, Familial 19

Characteristics:


Prevelance:

Ependymoma: 1-9/1000000 (Europe) 58

Age Of Onset:

Ependymoma: All ages 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:5500
MeSH 43 D004806
NCIt 49 C4713
SNOMED-CT 68 57706008
ICD10 via Orphanet 32 D43.2
UMLS via Orphanet 72 C0014474
Orphanet 58 ORPHA251636
UMLS 71 C0014474 C0334578 C1370500 more

Summaries for Cellular Ependymoma

Orphanet: 58 Ependymoma is the most frequent intramedullary tumor in adults (but accounts for only 10-12% of pediatric central nervous system tumors), and can be benign or anaplastic. Ependymoma arise from the ependymal cells of the cerebral ventricles, corticle rests and central canal of the spinal cord, and manifest with variable symptoms such headache, vomiting, seizures, focal neurological signs and loss of vision and can cause obstructive hydrocephalus in some cases.

MalaCards based summary: Cellular Ependymoma, also known as ependymoma, is related to spinal cord ependymoma and childhood supratentorial ependymoma. An important gene associated with Cellular Ependymoma is MEN1 (Menin 1), and among its related pathways/superpathways are Neuroscience and DNA Damage. The drugs Carboplatin and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and liver, and related phenotypes are ependymoma and migraine

GARD: 19 Ependymomas are rare glial tumors of the brain and spinal cord (Yokota et al., 2003).

Wikipedia: 75 An ependymoma is a tumor that arises from the ependyma, a tissue of the central nervous system. Usually,... more...

Related Diseases for Cellular Ependymoma

Diseases related to Cellular Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 596)
# Related Disease Score Top Affiliating Genes
1 spinal cord ependymoma 32.6 ZFTA RELA NF2
2 childhood supratentorial ependymoma 32.5 ZFTA RELA
3 rela fusion-positive ependymoma 32.5 ZFTA RELA
4 posterior fossa ependymoma 32.4 ZFTA RELA
5 tanycytic ependymoma 32.3 ZFTA RELA NF2 MSH2 MEN1 GFAP
6 childhood ependymoma 32.1 ZFTA RELA
7 papillary ependymoma 31.9 SYP S100B NF2 MSH2 MEN1 GFAP
8 benign ependymoma 31.7 ZFTA SYP RELA NF2 GFAP
9 clear cell ependymoma 30.8 ZFTA VIM SYP RELA NF2 MUC1
10 cauda equina syndrome 30.6 SYP GFAP
11 spinal cancer 30.6 ZFTA NF2 GFAP
12 central neurocytoma 30.6 SYP NES GFAP
13 embryonal tumor with multilayered rosettes, c19mc-altered 30.4 SYP GFAP
14 obstructive hydrocephalus 30.4 SYP NF2 GFAP
15 pleomorphic xanthoastrocytoma 30.4 ZFTA SYP MGMT
16 supratentorial ependymoma 30.4 ZFTA RELA NF2
17 diffuse astrocytoma 30.3 MGMT GFAP EGFR
18 oligoastrocytoma 30.1 MGMT GFAP
19 subependymal giant cell astrocytoma 30.1 SYP S100B GFAP
20 medulloepithelioma 30.1 SYP NES GFAP
21 pineal gland cancer 30.1 SYP GFAP
22 ganglioglioma 30.1 SYP S100B NES GFAP
23 neurilemmoma 30.0 VIM SYP S100B NF2 NES MUC1
24 teratoma 30.0 VIM SYP NES MUC1 GFAP
25 carcinoid tumors, intestinal 30.0 SYP MEN1
26 chordoid meningioma 29.9 SYP NF2
27 ganglioneuroma 29.9 SYP S100B GFAP
28 mucinous adenocarcinoma 29.9 MUC1 MSH2 EGFR
29 astroblastoma 29.9 ZFTA VIM RELA GFAP
30 choroid plexus cancer 29.9 ZFTA SYP S100B GFAP
31 meningothelial meningioma 29.9 NF2 GFAP
32 rhabdoid meningioma 29.8 VIM SYP NF2 GFAP
33 low grade glioma 29.8 SYP NES MGMT GFAP EGFR
34 anaplastic oligodendroglioma 29.8 NES MGMT GFAP EGFR
35 clear cell meningioma 29.8 SYP NF2 GFAP
36 rhabdoid cancer 29.8 VIM SYP MUC1
37 hydrocephalus 29.7 SYP S100B NES GFAP
38 high grade ependymoma 29.7 ZFTA RELA NF2 MGMT GFAP
39 high grade glioma 29.7 NES MGMT HOTAIR GFAP EGFR
40 hemangioblastoma 29.7 VIM SYP S100B MUC1 GFAP EGFR
41 papilloma of choroid plexus 29.7 SYP S100B MUC1 LINC01194 GFAP
42 chordoma 29.7 VIM S100B MUC1 GFAP EGFR
43 cystic teratoma 29.7 SYP MUC1
44 glioblastoma 29.7 NF2 NES MSH2 MGMT HOTAIR GFAP
45 bap1 tumor predisposition syndrome 29.7 NF2 MSH2 MEN1 EGFR
46 gemistocytic astrocytoma 29.7 S100B MGMT GFAP
47 spinal cord disease 29.6 SYP NF2 NES MGMT GFAP EGFR
48 adrenal carcinoma 29.6 VIM SYP MEN1
49 ewing sarcoma 29.5 VIM SYP S100B NES
50 supratentorial primitive neuroectodermal tumor 29.5 SYP GFAP

Graphical network of the top 20 diseases related to Cellular Ependymoma:



Diseases related to Cellular Ependymoma

Symptoms & Phenotypes for Cellular Ependymoma

Human phenotypes related to Cellular Ependymoma:

58 30 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ependymoma 58 30 Obligate (100%) Obligate (100%)
HP:0002888
2 migraine 58 30 Frequent (33%) Frequent (79-30%)
HP:0002076
3 pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0012531
4 abnormal cell morphology 58 30 Frequent (33%) Frequent (79-30%)
HP:0025461
5 seizure 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001250
6 gait disturbance 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001288
7 vomiting 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002013
8 spinal cord tumor 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010302
9 distal muscle weakness 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002460
10 dysesthesia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012534
11 supratentorial neoplasm 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030693
12 neoplasm of the lung 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100526
13 ovarian neoplasm 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100615
14 neoplasm of the liver 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002896
15 neoplasm of the breast 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100013

GenomeRNAi Phenotypes related to Cellular Ependymoma according to GeneCards Suite gene sharing:

25 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-111 9.78 MEN1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.78 MSH2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.78 EGFR
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.78 TP73
5 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.78 MEN1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-14 9.78 MSH2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.78 MSH2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.78 MEN1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-160 9.78 TIMP3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.78 TIMP3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.78 TIMP3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.78 MSH2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.78 TP73
14 Increased shRNA abundance (Z-score > 2) GR00366-A-204 9.78 TP73
15 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.78 TP73
16 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.78 EGFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.78 EGFR MSH2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.78 TIMP3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.78 EGFR TIMP3 TP73
20 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.78 MEN1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-53 9.78 MSH2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-59 9.78 TIMP3
23 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.78 TIMP3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.78 EGFR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.78 EGFR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-98 9.78 MEN1
27 Increased proliferation GR00094-A 8.96 MEN1 NF2

MGI Mouse Phenotypes related to Cellular Ependymoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 10.02 EGFR GFAP MEN1 MKI67 MUC1 RELA
2 nervous system MP:0003631 10 EGFR GFAP MEN1 MGMT MSH2 NES
3 homeostasis/metabolism MP:0005376 10 EGFR GFAP MEN1 MGMT MKI67 MSH2
4 neoplasm MP:0002006 9.97 EGFR MEN1 MGMT MKI67 MSH2 MUC1
5 digestive/alimentary MP:0005381 9.56 EGFR GFAP MEN1 MSH2 MUC1 NF2
6 respiratory system MP:0005388 9.23 EGFR MEN1 MGMT NF2 RELA TIMP3

Drugs & Therapeutics for Cellular Ependymoma

Drugs for Cellular Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904
2
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
3
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
4
Temozolomide Approved, Investigational Phase 2, Phase 3 85622-93-1 5394
5
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
6
Valproic acid Approved, Investigational Phase 2, Phase 3 99-66-1 3121
7
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
8
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
9
Picropodophyllin Approved, Investigational Phase 3 518-28-5, 477-47-4 10607 72435
10
Trofosfamide Investigational Phase 2, Phase 3 22089-22-1 65702
11 Antirheumatic Agents Phase 2, Phase 3
12 Alkylating Agents Phase 2, Phase 3
13 Antineoplastic Agents, Alkylating Phase 2, Phase 3
14
Etoposide phosphate Phase 2, Phase 3 16760419
15 Immunosuppressive Agents Phase 2, Phase 3
16 Immunologic Factors Phase 2, Phase 3
17 Psychotropic Drugs Phase 2, Phase 3
18 Anticonvulsants Phase 2, Phase 3
19 Antimitotic Agents Phase 3
20 Keratolytic Agents Phase 3
21 Tubulin Modulators Phase 3
22
Lenograstim Approved, Investigational Phase 2 135968-09-1
23
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
24
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
25
Sargramostim Approved, Investigational Phase 2 123774-72-1
26
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
27
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
28
Ivosidenib Approved, Investigational Phase 2 1448347-49-6 78140854 71657455
29
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
30
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
31
Fenofibric acid Approved Phase 2 42017-89-0 64929
32
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
33
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
34
Nivolumab Approved Phase 2 946414-94-4
35
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
36
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
37
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
38
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
39
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286
40
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
41
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
42
Olaparib Approved Phase 2 763113-22-0 23725625
43
Carbamide peroxide Approved Phase 2 124-43-6
44
Acetaminophen Approved Phase 2 103-90-2 1983
45
Iodine Approved, Investigational Phase 2 7553-56-2 807
46
Ondansetron Approved, Withdrawn Phase 2 99614-02-5 4595
47
Histamine Approved, Investigational Phase 2 51-45-6 774
48
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
49
Promethazine Approved, Investigational Phase 2 60-87-7 4927
50
Vinblastine Approved Phase 2 865-21-4 241903 13342

Interventional clinical trials:

(show top 50) (show all 148)
# Name Status NCT ID Phase Drugs
1 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
2 Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents Completed NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;intraventricular etoposide;trofosfamide, etoposide
3 An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
4 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years Active, not recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine
5 Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
6 Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
7 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
8 A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma Completed NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
9 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
10 A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients Completed NCT01462695 Phase 2 Sunitinib Malate
11 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
12 Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial Completed NCT01295944 Phase 2 Carboplatin;Bevacizumab
13 A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
14 Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
15 A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
16 A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2 Bevacizumab;Lapatinib
17 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
18 SIOP Study of Combined Modality Treatment in Childhood Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
19 A Phase II Study of Pemetrexed in Children With Recurrent Malignancies Completed NCT00520936 Phase 2 pemetrexed
20 Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020) Completed NCT04730349 Phase 1, Phase 2
21 Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
22 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
23 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
24 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
25 A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS Completed NCT00002876 Phase 2 cisplatin;etoposide
26 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
27 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations Recruiting NCT04284774 Phase 2 Tipifarnib
28 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations Recruiting NCT04195555 Phase 2 Ivosidenib
29 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations Recruiting NCT04320888 Phase 2 Selpercatinib
30 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib Sulfate
31 A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma and ATRT Recruiting NCT01356290 Phase 2 Bevacizumab;Thalidomide;Celecoxib;Fenofibric acid;Etoposide;Cyclophosphamide;Etoposide phosphate;Cytarabine
32 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib;Neratinib
33 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2 Methionine
34 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
35 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
36 Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG Recruiting NCT04049669 Phase 2 Indoximod;Temozolomide;Cyclophosphamide;Etoposide;Lomustine
37 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib Sulfate;Olaparib;Palbociclib;Samotolisib;Selpercatinib;Selumetinib Sulfate;Tazemetostat;Tipifarnib;Ulixertinib;Vemurafenib
38 NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors Recruiting NCT03213678 Phase 2 Samotolisib
39 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes Active, not recruiting NCT03526250 Phase 2 Palbociclib
40 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes Active, not recruiting NCT03233204 Phase 2 Olaparib
41 Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma Active, not recruiting NCT04743661 Phase 2 Irinotecan;Temozolomide;Bevacizumab;Omburtamab I-131;Liothyronine;SSKI;Dexamethasone;Antipyretic;Antihistamine;anti-emetics
42 A Phase II Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma Active, not recruiting NCT02125786 Phase 2 ^1^8F-Fluorodeoxyglucose;^1^1C-methionine
43 Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Active, not recruiting NCT00602667 Phase 2 Induction Chemotherapy;Low-Risk Therapy;High-Risk Therapy;Intermediate-Risk Therapy
44 Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma Active, not recruiting NCT02155920 Phase 2 Everolimus
45 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations Active, not recruiting NCT03698994 Phase 2 Ulixertinib
46 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex Active, not recruiting NCT03213665 Phase 2 Tazemetostat
47 Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study Active, not recruiting NCT03194906 Phase 2 Memantine
48 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations Active, not recruiting NCT03220035 Phase 2 Vemurafenib
49 A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation: An Assessment of Long Term Neurocognitive, Neuroendocrine Adn Ototoxicity Outcomes Active, not recruiting NCT01288235 Phase 2
50 Phase I/II Study of Lutathera in Pediatric and Young Adult Patients With Recurrent and/or Progressive High-Grade Central Nervous System Tumors and Meningiomas That Express Somatostatin Type2A Receptors and Demonstrate Uptake on DOTATATE PET Not yet recruiting NCT05278208 Phase 1, Phase 2 LUTATHERA® (Lutetium Lu 177 dotatate)

Search NIH Clinical Center for Cellular Ependymoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine

Genetic Tests for Cellular Ependymoma

Genetic tests related to Cellular Ependymoma:

# Genetic test Affiliating Genes
1 Ependymoma 28

Anatomical Context for Cellular Ependymoma

Organs/tissues related to Cellular Ependymoma:

MalaCards : Spinal Cord, Brain, Liver, T Cells, Breast, Lung, Nk Cells

Publications for Cellular Ependymoma

Articles related to Cellular Ependymoma:

(show top 50) (show all 4283)
# Title Authors PMID Year
1
Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. 53 62
19724855 2009
2
Podoplanin is a potential marker for the diagnosis of ependymoma: a comparative study with epithelial membrane antigen (EMA). 53 62
19788053 2009
3
[Expression of epidermal growth factor receptor and Ki-67 antigen in brain ependymoma and the correlation between them]. 53 62
19257969 2008
4
EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. 53 62
18386816 2008
5
Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. 53 62
18552083 2008
6
Nestin expression in different tumours and its relevance to malignant grade. 53 62
17873113 2008
7
Immunohistochemical study of CD99 and EMA expression in ependymomas. 53 62
18382710 2008
8
Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. 53 62
17206475 2007
9
New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors. 53 62
17284108 2007
10
Immunohistochemical profile and chromosomal imbalances in papillary tumours of the pineal region. 53 62
16640646 2006
11
p53 Pathway dysfunction in primary childhood ependymomas. 53 62
16086408 2006
12
Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. 53 62
16609018 2006
13
Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. 53 62
16616114 2006
14
Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. 53 62
16146813 2005
15
Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. 53 62
16051033 2005
16
A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas. 53 62
15635072 2005
17
Light microscopic demonstration of the microlumen of ependymoma: a study of the usefulness of antigen retrieval for epithelial membrane antigen (EMA) immunostaining. 53 62
15696964 2004
18
Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas. 53 62
12898159 2003
19
March 2003: a 41 -year-old female with a solitary lesion in the liver. 53 62
12946033 2003
20
Complex cytogenetic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma. 53 62
12505253 2002
21
The expression of p73, p21 and MDM2 proteins in gliomas. 53 62
12241107 2002
22
Immunohistochemical markers for prognosis of ependymal neoplasms. 53 62
12187959 2002
23
Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas. 53 62
12011257 2002
24
Analysis of the NF2 gene in oligodendrogliomas and ependymomas. 53 62
11996787 2002
25
p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases. 53 62
11585252 2001
26
Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo. 53 62
11561758 2001
27
Mutation analysis of the p73 gene in nonastrocytic brain tumours. 53 62
11461077 2001
28
Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. 53 62
11275983 2001
29
Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. 53 62
10967185 2000
30
Receptor-mediated endocytosis of transthyretin by ependymoma cells. 53 62
10869517 2000
31
The immunophenotype of ependymomas. 53 62
10937045 2000
32
Low frequency of SV40, JC and BK polyomavirus sequences in human medulloblastomas, meningiomas and ependymomas. 53 62
10668898 2000
33
Ovarian ependymoma. A case report. 53 62
10982025 2000
34
Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2. 53 62
10584875 1999
35
Expression of the simian virus 40 large tumor antigen (Tag) and formation of Tag-p53 and Tag-pRb complexes in human brain tumors. 53 62
10570441 1999
36
Atypical central neurocytoma: report of a case. 53 62
10502912 1999
37
Cerebellar papillary meningioma in a 3-year-old boy: the usefulness of electron microscopy for diagnosis. 53 62
10403309 1999
38
Molecular genetic analysis of non-astrocytic gliomas. 53 62
10231401 1999
39
Signet-ring cell ependymoma: case report with implications for pathogenesis and differential diagnosis. 53 62
10631722 1999
40
Tissue culture of human neurocytomas induces the expression of glial fibrilary acidic protein. 53 62
10451427 1998
41
O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. 53 62
9815647 1997
42
Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas. 53 62
9329458 1997
43
Paraganglioma of the cauda equina. A case report and review of the literature. 53 62
8611199 1996
44
The ultrastructure of ependymoma: personal experience and the review of the literature. 53 62
9812425 1996
45
Loss of heterozygosity on chromosome 10, 13q(Rb), 17p, and p53 gene mutations in human brain gliomas. 53 62
8924230 1995
46
Expression of non-glial intermediate filament proteins in gliomas. 53 62
7518371 1994
47
Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. 53 62
7511316 1994
48
Cauda equina tumor with ependymal and paraganglionic differentiation. 53 62
1612583 1992
49
Epidermal growth factor receptor in human brain tumors. 53 62
1560188 1992
50
[Immunohistochemical study for choroid plexus papillomas and ependymomas]. 53 62
1726244 1991

Variations for Cellular Ependymoma

ClinVar genetic disease variations for Cellular Ependymoma:

5 (show all 36)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MEN1 NM_001370259.2(MEN1):c.696dup (p.Lys233fs) DUP Pathogenic
487778 rs1555165565 GRCh37: 11:64575111-64575111
GRCh38: 11:64807638-64807639
2 NF2 NM_000268.4(NF2):c.551G>A (p.Trp184Ter) SNV Likely Pathogenic
487796 rs1555993293 GRCh37: 22:30051617-30051617
GRCh38: 22:29655628-29655628
3 MSH2 NM_000251.3(MSH2):c.482T>C (p.Val161Ala) SNV Likely Pathogenic
565544 rs63750126 GRCh37: 2:47637348-47637348
GRCh38: 2:47410209-47410209
4 overlap with 76 genes dup(11)(q13.1q13.1) DUP Likely Pathogenic
634998 GRCh37: 11:63533279-65429676
GRCh38:
5 POU3F4 NM_000307.5(POU3F4):c.1013C>T (p.Pro338Leu) SNV Uncertain Significance
487785 rs1555984638 GRCh37: X:82764345-82764345
GRCh38: X:83509337-83509337
6 KREMEN2 NM_172229.3(KREMEN2):c.494G>T (p.Gly165Val) SNV Uncertain Significance
487788 rs1210829529 GRCh37: 16:3016650-3016650
GRCh38: 16:2966649-2966649
7 HSD3B2 NM_000198.4(HSD3B2):c.1004G>A (p.Arg335Gln) SNV Uncertain Significance
487802 rs985808078 GRCh37: 1:119965128-119965128
GRCh38: 1:119422505-119422505
8 TRAF3 NM_145725.3(TRAF3):c.53C>G (p.Pro18Arg) SNV Uncertain Significance
487799 rs145456077 GRCh37: 14:103336591-103336591
GRCh38: 14:102870254-102870254
9 GON4L NM_001282860.2(GON4L):c.2455A>G (p.Asn819Asp) SNV Uncertain Significance
487779 rs1553200563 GRCh37: 1:155742897-155742897
GRCh38: 1:155773106-155773106
10 ARHGAP32 NM_001378024.1(ARHGAP32):c.4745C>G (p.Thr1582Ser) SNV Uncertain Significance
487793 rs749174548 GRCh37: 11:128840363-128840363
GRCh38: 11:128970468-128970468
11 NET1 NM_001047160.3(NET1):c.498G>T (p.Glu166Asp) SNV Uncertain Significance
487790 rs1554818513 GRCh37: 10:5494455-5494455
GRCh38: 10:5452492-5452492
12 CACNG2 NM_006078.5(CACNG2):c.541T>C (p.Tyr181His) SNV Uncertain Significance
487807 rs1555892196 GRCh37: 22:36960829-36960829
GRCh38: 22:36564782-36564782
13 TRPM1 NM_001252024.2(TRPM1):c.283A>C (p.Ile95Leu) SNV Uncertain Significance
487810 rs1555424877 GRCh37: 15:31360292-31360292
GRCh38: 15:31068089-31068089
14 KAT6B NM_012330.4(KAT6B):c.3827C>T (p.Pro1276Leu) SNV Uncertain Significance
487787 rs1554845417 GRCh37: 10:76788409-76788409
GRCh38: 10:75028651-75028651
15 TXNRD2 NM_006440.5(TXNRD2):c.1432G>C (p.Ala478Pro) SNV Uncertain Significance
487801 rs1555906972 GRCh37: 22:19865626-19865626
GRCh38: 22:19878103-19878103
16 SETD9 NM_153706.4(SETD9):c.788_796del (p.Ile263_Tyr265del) DEL Uncertain Significance
487781 rs1554039146 GRCh37: 5:56210766-56210774
GRCh38: 5:56914939-56914947
17 TASOR NM_001365635.2(TASOR):c.97G>A (p.Glu33Lys) SNV Uncertain Significance
487784 rs1553733337 GRCh37: 3:56716938-56716938
GRCh38: 3:56682910-56682910
18 VBP1 NM_003372.7(VBP1):c.331C>A (p.Leu111Met) SNV Uncertain Significance
487792 rs1000821034 GRCh37: X:154456711-154456711
GRCh38: X:155228429-155228429
19 KLHL21 NM_014851.4(KLHL21):c.501G>C (p.Glu167Asp) SNV Uncertain Significance
487795 rs1292721663 GRCh37: 1:6662377-6662377
GRCh38: 1:6602317-6602317
20 MAP4K3 NM_003618.4(MAP4K3):c.899T>C (p.Phe300Ser) SNV Uncertain Significance
487798 rs1268580645 GRCh37: 2:39552678-39552678
GRCh38: 2:39325537-39325537
21 RET NM_020975.6(RET):c.1202G>A (p.Ser401Asn) SNV Uncertain Significance
620604 rs1564493414 GRCh37: 10:43604617-43604617
GRCh38: 10:43109169-43109169
22 SYNE1 NM_182961.4(SYNE1):c.11097C>G (p.Phe3699Leu) SNV Uncertain Significance
487805 rs1554520414 GRCh37: 6:152674554-152674554
GRCh38: 6:152353419-152353419
23 BANP NM_001386991.1(BANP):c.692A>G (p.Asn231Ser) SNV Uncertain Significance
487782 rs1555586650 GRCh37: 16:88052070-88052070
GRCh38: 16:88018464-88018464
24 SH3TC2 NM_024577.4(SH3TC2):c.3016del (p.Ser1006fs) DEL Uncertain Significance
487808 rs1554121513 GRCh37: 5:148406172-148406172
GRCh38: 5:149026609-149026609
25 SPRY3 NM_001304990.2(SPRY3):c.55C>T (p.Arg19Cys) SNV Uncertain Significance
487791 rs779201129 GRCh37: Y:59106594-59106594
GRCh38: X:155773926-155773926
26 OTUD5 NM_001136157.2(OTUD5):c.1687C>A (p.Pro563Thr) SNV Uncertain Significance
487794 rs1295653938 GRCh37: X:48780465-48780465
GRCh38: X:48923188-48923188
27 GLB1 NM_000404.4(GLB1):c.1903G>C (p.Ala635Pro) SNV Uncertain Significance
487803 rs1553604701 GRCh37: 3:33038668-33038668
GRCh38: 3:32997176-32997176
28 HDAC3 NM_003883.4(HDAC3):c.50_55+5del DEL Uncertain Significance
487780 rs1554218152 GRCh37: 5:141016298-141016308
GRCh38: 5:141636731-141636741
29 LETM1 NM_012318.3(LETM1):c.286G>A (p.Val96Met) SNV Uncertain Significance
487800 rs753905629 GRCh37: 4:1843382-1843382
GRCh38: 4:1841655-1841655
30 LATS1 NM_004690.4(LATS1):c.2365G>C (p.Asp789His) SNV Uncertain Significance
487797 rs750318192 GRCh37: 6:150001239-150001239
GRCh38: 6:149680103-149680103
31 ADGRA2 NM_032777.10(ADGRA2):c.1316_1334del (p.Asn439fs) DEL Uncertain Significance
487806 rs1554525957 GRCh37: 8:37691223-37691241
GRCh38: 8:37833705-37833723
32 SUV39H1 NM_003173.4(SUV39H1):c.415C>T (p.Arg139Cys) SNV Uncertain Significance
487783 rs368779259 GRCh37: X:48558731-48558731
GRCh38: X:48700340-48700340
33 SLC39A11 NM_139177.4(SLC39A11):c.595G>T (p.Val199Phe) SNV Uncertain Significance
487809 rs745762301 GRCh37: 17:70845779-70845779
GRCh38: 17:72849640-72849640
34 DEPDC5 NM_001242896.3(DEPDC5):c.2939G>A (p.Trp980Ter) SNV Uncertain Significance
487789 rs1555900957 GRCh37: 22:32241141-32241141
GRCh38: 22:31845155-31845155
35 PATZ1 NM_014323.3(PATZ1):c.562G>T (p.Asp188Tyr) SNV Uncertain Significance
487786 rs1555894069 GRCh37: 22:31741027-31741027
GRCh38: 22:31345041-31345041
36 MT-ND4 NC_012920.1:m.11032delA DEL Uncertain Significance
487804 rs1556423884 GRCh37: MT:11032-11032
GRCh38: MT:11032-11032

Copy number variations for Cellular Ependymoma from CNVD:

6 (show top 50) (show all 1024)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13823 1 1 7200000 Deletion Ependymoma
2 15495 1 116080654 116108285 Amplification NHLH2 Ependymoma
3 15648 1 117745152 117779348 Deletion MAN1A2 Ependymoma
4 19381 1 150034000 245120000 Amplification Ependymoma
5 19382 1 150034000 245120000 Amplification Ependymoma
6 26308 1 198898833 198920273 Amplification LGR6 Ependymoma
7 31595 1 2869431 2902617 Amplification TLR5 Ependymoma
8 31803 1 3118000 5001000 Deletion Ependymoma
9 38299 10 101279725 101300855 Deletion Ependymoma
10 38453 10 102724768 102752246 Deletion LZTS2 Ependymoma
11 38454 10 102724768 102752246 Deletion MRPL43 Ependymoma
12 38455 10 102724768 102752246 Deletion TWNK Ependymoma
13 38456 10 102724768 102752246 Deletion SEMA4G Ependymoma
14 38866 10 105634726 105742493 Deletion STN1 Ependymoma
15 38867 10 105634726 105742493 Deletion SLK Ependymoma
16 38979 10 106855945 106907237 Deletion SORCS3 Ependymoma
17 39169 10 11151805 11236375 Deletion CELF2 Ependymoma
18 40763 10 13344307 13497936 Deletion PHYH Ependymoma
19 40764 10 13344307 13497936 Deletion SEPHS1 Ependymoma
20 40806 10 133827559 133847021 Amplification JAKMIP3 Ependymoma
21 40809 10 133852261 133910912 Deletion DPYSL4 Ependymoma
22 40810 10 133852261 133910912 Deletion STK32C Ependymoma
23 40887 10 134410586 134892955 Deletion CFAP46 Ependymoma
24 40888 10 134410586 134892955 Deletion CFAP46 Ependymoma
25 40889 10 134410586 134892955 Deletion ADGRA1 Ependymoma
26 40890 10 134410586 134892955 Deletion INPP5A Ependymoma
27 40891 10 134410586 134892955 Deletion KNDC1 Ependymoma
28 40892 10 134410586 134892955 Deletion Ependymoma
29 41033 10 135073302 135095235 Amplification ECHS1 Ependymoma
30 41034 10 135073302 135095235 Amplification PAOX Ependymoma
31 41074 10 135176625 135276748 Deletion CYP2E1 Ependymoma
32 41075 10 135176625 135276748 Deletion SPRNP1 Ependymoma
33 41076 10 135176625 135276748 Deletion SYCE1 Ependymoma
34 41910 10 25665327 25756077 Deletion GPR158 Ependymoma
35 42307 10 3169189 3180797 Deletion PITRM1 Ependymoma
36 44077 10 5175582 5187881 Deletion AKR1C8 Ependymoma
37 44224 10 53651276 53712562 Deletion PRKG1 Ependymoma
38 44704 10 6170011 6268419 Deletion RBM17 Ependymoma
39 45199 10 68970214 69114993 Deletion CTNNA3 Ependymoma
40 45273 10 69645873 69701073 Deletion ATOH7 Ependymoma
41 45408 10 70846341 70896472 Deletion TSPAN15 Ependymoma
42 45468 10 71234506 71351772 Deletion COL13A1 Ependymoma
43 45538 10 71990162 72295747 Deletion ADAMTS14 Ependymoma
44 45539 10 71990162 72295747 Deletion TBATA Ependymoma
45 45540 10 71990162 72295747 Deletion PALD1 Ependymoma
46 45541 10 71990162 72295747 Deletion PRF1 Ependymoma
47 45542 10 71990162 72295747 Deletion SGPL1 Ependymoma
48 45578 10 72636128 72774965 Deletion SLC29A3 Ependymoma
49 45579 10 72636128 72774965 Deletion UNC5B Ependymoma
50 45628 10 73121579 73231404 Deletion VSIR Ependymoma

Expression for Cellular Ependymoma

Search GEO for disease gene expression data for Cellular Ependymoma.

Pathways for Cellular Ependymoma

Pathways related to Cellular Ependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.09 SYP S100B NF2 MKI67 GFAP
2 11.82 VIM TP73 MSH2 MKI67 MGMT
3
Show member pathways
11.67 S100B GFAP EGFR
4 11.6 TP73 MSH2 EGFR
5 11.49 VIM GFAP EGFR
6 10.92 VIM SYP S100B NES GFAP

GO Terms for Cellular Ependymoma

Cellular components related to Cellular Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament cytoskeleton GO:0045111 9.1 VIM NES GFAP

Biological processes related to Cellular Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to UV-B GO:0010224 9.46 RELA MSH2
2 Schwann cell proliferation GO:0014010 9.26 NF2 GFAP
3 intermediate filament-based process GO:0045103 8.62 VIM GFAP

Sources for Cellular Ependymoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....